Home Overview Press Room Blog Publications For Students about us

Biotech & Pharma : Displaying 11-20 of 2118

Why Some Parents Choose to Have a Deaf Babyby Rich WordsworthMotherboardSeptember 29th, 2015Genetic deafness is one of many conditions that can be screened for using PGD. That’s led to a surprising phenomenon: deaf parents using PGD not to avoid deafness, but to deliberately select for it.
DARPA Gives MIT Lab $32 Million to Program Living Cellsby Alexandra OssolaPopular ScienceSeptember 29th, 2015Synthetic biology lab the Broad Institute Foundry announced a new defense contract to join computer scientists and companies in "chemicals, pharmaceuticals, food, energy, agriculture, and biotechnology," but the work remains vague.
Who has your DNA—or wants itby Jocelyn KaiserScienceSeptember 25th, 2015More and more groups are amassing computer server–busting amounts of human DNA. Science's informal survey found at least 17 biobanks that hold—or plan to hold—genomic data on 75,000 or more people.
Can 23andMe have it all?by Kelly ServickScienceSeptember 25th, 2015Amid 30 recent deals with biotech and pharma companies, 23andMe hired Genentech retiree Richard Scheller who plans to hire 25 scientists in the next year to begin drug development based off the direct-to-consumer genomic database.
New CRISPR Protein Slices through Genomes, Patent Problemsby Antonio RegaladoMIT Technology ReviewSeptember 25th, 2015With patent rights and Nobel Prize announcements pending, Feng Zhang at the Broad Institute reports new CRISPR gene editing enzyme Cpf1 to compete with the hyped CRISPR-Cas9 system.
A $6 Billion Question: Affordability of California's Stem Cell Therapiesby David JensenCalifornia Stem Cell ReportSeptember 23rd, 2015The California stem cell agency will cost taxpayers $6 billion by 2020. But the agency isn't discussing what any therapies are likely to cost, or whether it should focus on affordable treatments.
The Life of a Professional Guinea Pigby Cari RommThe AtlanticSeptember 23rd, 2015Phase 1 trials are almost always where the money is. Is paying vulnerable populations to participate in dangerous drug studies the equivalent of coercion?
The hidden risks for 'three-person' babiesby Garry HamiltonNature NewsSeptember 23rd, 2015"There's a definite possibility you'd see things like disrupted fertility function, various forms of metabolic syndromes and changes in things that relate to metabolism in general."
Down Syndrome Blood Test Sparks Abortion Debateby Amy Dockser MarcusWall Street JournalSeptember 21st, 2015Advocates worry that more accurate prenatal tests will lead more people to end pregnancies without understanding how life with Down syndrome has dramatically changed.
Can knowing you and your family may get Alzheimer’s ever be positive?by Giulia RhodesThe GuardianSeptember 21st, 2015In the vast majority of cases, the cause of Alzheimer’s remains unclear, a complex interplay of environmental and genetic factors not yet fully understood.
Displaying 11-20 of 2118  
< Prev  Next >> 
« First Page Last Page » 
« Show Complete List » 


home | overview | blog | publications| about us | donate | newsletter | press room | privacy policy

CGS • 1936 University Ave, Suite 350, Berkeley, CA 94704 • • (p) 1.510.665.7760 • (F) 1.510.665.8760